Tvardi Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.863 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 11.51M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI...